Keros Therapeutics, Inc. (NASDAQ: KROS) is a Healthcare company (Biotechnology) with a market capitalization of $222M. The Maz Rating grades it against the other companies in its sector.
Keros Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $11.31, Keros Therapeutics, Inc. trades at 5.4x sales and 0.8x book value, with an EV/EBITDA of 0.4. Over the last twelve months it generated about $41M of revenue and a net loss of $56M. It runs a gross margin of 98.0%, an operating margin of -179.7% and a net margin of -151.4%. It shows return on equity of -21.8%, return on invested capital of -24.6% and a free cash flow yield of -21.7%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 18.14. Over the past 52 weeks the share price ranged from $8.98 to $22.55, with a beta of 1.02.
Keros Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 10 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Keros Therapeutics, Inc. (KROS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 118.8% / 30% · Interest income / Revenue 0.14% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 118.8% / 33% · Receivables / Mkt Cap (36m) 10.5% / 49% · Interest income / Revenue 0.14% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 118.8% / 33.33% · Receivables / Mkt Cap (24m) 10.5% / 33.33% · Interest income / Revenue 0.14% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.37% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 87.2% / 33.33% · Receivables / Avg Assets (4Q) 2.80% / 33.33% · Interest income / Revenue 0.14% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 84.4% / 33.33% · (Cash+Recv) / Total Assets 91.8% / 33.33% · Interest income / Revenue 0.14% / 5% | Fail |
No. As of September 2026, Keros Therapeutics, Inc. (KROS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Keros Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 0.14% of each dividend: Keros Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.